MCM
CGTX icon

MAI Capital Management’s Cognition Therapeutics CGTX Stock Holding History

MAI Capital Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$190 Hold
250
– – ﹤0.01% 4635
2025
Q4 		$338 Hold
250
– – ﹤0.01% 3938
2025
Q3 		$338 Buy
250
+50
+25% +$68 ﹤0.01% 3661
2025
Q2 		$62 Hold
200
– – ﹤0.01% 3910
2025
Q1 		$85 Hold
200
– – ﹤0.01% 3369
2024
Q4 		$141 Buy
+200
New +$99 ﹤0.01% 3405

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

MAI Capital Management's CGTX Position: Q1 2026 in Review

MAI Capital Management held its Cognition Therapeutics (CGTX) position steady in Q1 2026 at 250 shares worth $190. The position accounts for ﹤0.01% of the portfolio, ranked #4635.

MAI Capital Management first reported a position in CGTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $338 in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • MAI Capital Management held 250 shares of Cognition Therapeutics worth $190 as of Q1 2026.
  • MAI Capital Management left its Cognition Therapeutics share count unchanged in Q1 2026.
  • Cognition Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4635 holding.
  • MAI Capital Management first reported a position in Cognition Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • MAI Capital Management's Cognition Therapeutics position peaked at $338 in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.